Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Sign in

Welcome!Log into your account

your username

your password

Forgot your password?

Password recovery

Recover your password

your email

Search

Medicines Law & Policy Research and resources on intellectual property and health

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Tag: GAVI

The € 7.4 billion for Covid-19 product and vaccine development needs...

Ellen 't Hoen - May 5, 2020

Recent Posts

TRIPS Council to discuss IP and the public interest in the context of Covid-19
Remdesivir developed country price announced
COVID-19 Technology Access Pool (C-TAP): A Promising Human Rights Approach
Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global access to COVID-19 health technologies through pooling of knowledge, intellectual property and data

Posts by Subject

Access to Medicines ARIPO Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Data exclusivity Delinkage DNDi dolutegravir European Union evergreening France Gilead Hepatitis C HIV IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs Patent patent opposition Patents PrEP R&D remdesivir Sofosbuvir SPC Supplementary Protection Certificates The Netherlands transparency TRIPS flexibilities Truvada United Nations High Level Panel vaccines WHO WIPO WTO

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: info@medicineslawandpolicy.net.

This work is licensed under Creative Commons.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok